C-RAD AB Series B
C-Rad AB (publ) develops, manufactures, and sells products and systems with applications in radiotherapy for the treatment of cancer in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company offers Catalyst+ HD, a patient positioning, intra-fraction motion management, and respiratory gating solution for conventional and stereotactic treatment delivery; Catalyst+, a solut… Read more
C-RAD AB Series B (0R44) - Net Assets
Latest net assets as of December 2021: Skr231.10 Million SEK
Based on the latest financial reports, C-RAD AB Series B (0R44) has net assets worth Skr231.10 Million SEK as of December 2021.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr306.70 Million) and total liabilities (Skr75.60 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr231.10 Million |
| % of Total Assets | 75.35% |
| Annual Growth Rate | 34.13% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 57.36 |
C-RAD AB Series B - Net Assets Trend (2017–2021)
This chart illustrates how C-RAD AB Series B's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for C-RAD AB Series B (2017–2021)
The table below shows the annual net assets of C-RAD AB Series B from 2017 to 2021.
| Year | Net Assets | Change |
|---|---|---|
| 2021-12-31 | Skr231.10 Million | +15.67% |
| 2020-12-31 | Skr199.79 Million | +139.74% |
| 2019-12-31 | Skr83.33 Million | -11.01% |
| 2018-12-31 | Skr93.64 Million | +31.14% |
| 2017-12-31 | Skr71.41 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to C-RAD AB Series B's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 20007500000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2021)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr231.10 Million | 100.00% |
| Total Equity | Skr231.10 Million | 100.00% |
C-RAD AB Series B Competitors by Market Cap
The table below lists competitors of C-RAD AB Series B ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hospital Mater Dei S.A
SA:MATD3
|
$54.42 Million |
|
AB VILKUSKIU PIEN.EO 029
F:UDW
|
$54.43 Million |
|
FingerMotion Inc
NASDAQ:FNGR
|
$54.44 Million |
|
Meiloon Industrial Co Ltd
TW:2477
|
$54.46 Million |
|
AGF A/S
CO:AGF-B
|
$54.42 Million |
|
LABORATORIO REIG J.EO 05
F:FEQ1
|
$54.40 Million |
|
American Crystal Sugar Company PFD REST NON DIV
PINK:ASCS
|
$54.40 Million |
|
Dongkuk Industries Co. Ltd
KQ:005160
|
$54.39 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in C-RAD AB Series B's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2020 to 2021, total equity changed from 199,789,000 to 231,100,000, a change of 31,311,000 (15.7%).
- Net income of 25,100,000 contributed positively to equity growth.
- Share repurchases of 4,200,000 reduced equity.
- Other factors increased equity by 10,411,000.
Equity Change Factors (2020 to 2021)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr25.10 Million | +10.86% |
| Share Repurchases | Skr4.20 Million | -1.82% |
| Other Changes | Skr10.41 Million | +4.5% |
| Total Change | Skr- | 15.67% |
Book Value vs Market Value Analysis
This analysis compares C-RAD AB Series B's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently C-RAD AB Series B utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.86%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 9.61%
- • Asset Turnover: 0.85x
- • Equity Multiplier: 1.33x
- Recent ROE (10.86%) is above the historical average (1.77%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -15.27% | -8.19% | 1.13x | 1.65x | Skr-18.05 Million |
| 2018 | 22.63% | 11.15% | 1.30x | 1.57x | Skr11.83 Million |
| 2019 | -16.56% | -6.72% | 1.30x | 1.89x | Skr-22.13 Million |
| 2020 | 7.19% | 6.48% | 0.82x | 1.35x | Skr-5.61 Million |
| 2021 | 10.86% | 9.61% | 0.85x | 1.33x | Skr1.99 Million |
Industry Comparison
This section compares C-RAD AB Series B's net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| C-RAD AB Series B (0R44) | Skr231.10 Million | -15.27% | 0.33x | $54.42 Million |
| Nyfosa AB (0A0K) | $13.33 Billion | 16.69% | 1.39x | $961.70 Million |
| Tethys Oil AB (0A1V) | $256.60 Million | 6.51% | 0.11x | $122.95 Million |
| High Templar Tech Limited (0A2T) | $12.04 Billion | -3.01% | 0.06x | $258.24 Million |
| Strategy Inc (0A7O) | $605.73 Million | 3.00% | 0.54x | $37.86 Billion |
| NACON SASU (0A9N) | $40.77 Million | 2.41% | 0.74x | $7.35 Million |
| Antin Infrastructure Partners (0AA5) | $32.26 Million | 152.50% | 1.23x | $579.46 Million |
| Truecaller AB Series B (0AA7) | $145.93 Million | -10.64% | 1.99x | $271.46 Million |
| Brockhaus Technologies AG (0AAW) | $315.34 Million | 15.55% | 1.46x | $75.78 Million |
| Hyloris Pharmaceuticals S.A. (0AB6) | $39.07 Million | -39.37% | 0.22x | $71.96 Million |
| Kalray S.A. (0ABT) | $54.02 Million | -28.78% | 0.63x | $33.84 Million |